Quotables
"For a list of all the ways technology has failed to improve the quality of life, please press three."
Alice Kahn
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8105615 | Lactoferrin as an adjuvant in cancer vaccines The present invention relates to methods of treating cancer by administering a composition of lactoferrin (LF) in combination with cancer vaccines. ... | 01/31/2012 |
| 8101195 | Artificial lymph node for treating cancer Provided is an artificial lymph node that is persistently effective in cancer treatment in vivo. A method of producing an artificial lymph node capable of inducing cancer antigen-specific immune responses, comprising the following steps: (a) a step for immuni... | 01/24/2012 |
| 8062646 | Tissue vaccines and uses thereof Compositions comprising a tissue vaccine that include a mixture of heterogeneous tissue obtained from tumors and connective tissues. Vaccines comprising these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition... | 11/22/2011 |
| 8034360 | Use of human prostate cell lines in cancer treatment The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, na... | 10/11/2011 |
| 8029808 | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M ... | 10/04/2011 |
| 7998491 | Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide The invention discloses a useful and novel factor (polypeptide) which plays an important role for morbid vascular smooth muscle in restenosis after percutaneous transluminal coronary angioplasty (PTCA) and arterial sclerosis in the field of cardiovascular system. | 08/16/2011 |
| 7976852 | Compositions and methods for cancer immunotherapy The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds o... | 07/12/2011 |
| 7939090 | System and method for the treatment of cancer, including cancers of the central nervous system The invention relates to the treatment of cancer, and particularly to the treatment of cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, including the administration of a dendritic cell-based cancer vacc... | 05/10/2011 |
| 7901693 | Compositions and methods for WT1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that sp... | 03/08/2011 |
| 7887822 | Peptides for stimulating an immune response against melanoma Provided in the present invention are recombinant peptides and a method for using the peptides in stimulating an immune response against human high molecular weight-melanoma associated antigen (HMW-MAA). The peptides were designed from the identification of regions ... | 02/15/2011 |
| 7807186 | Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encode... | 10/05/2010 |
| 7740871 | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide s... | 06/22/2010 |
| 7740872 | Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain in... | 06/22/2010 |
| 7691396 | Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins. ... | 04/06/2010 |
| 7670611 | Cancer immunotherapy with semi-allogeneic cells The present invention relates to improved semi-allogeneic immunogenic cells which act to stimulate and induce an immunological response when administered to an individual. In particular, it relates to cells which express both allogeneic and syngeneic MHC determinant... | 03/02/2010 |
| 7658935 | Methods and compositions for stimulating the immune system Methods for stimulating the immune system of an individual to produce and release antimalignin antibody are disclosed. The method comprises administering an amount of a composition containing malignin, recognin M, recognin L, or a peptide having the immunological sp... | 02/09/2010 |
| 7655249 | Compositions and methods for WT1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that sp... | 02/02/2010 |
| 7628996 | Sterile immunogenic non-tumorigenic tumor cell compositions and methods This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recu... | 12/08/2009 |
| 7601359 | Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition compr... | 10/13/2009 |
| 7585512 | Composition and method of using tumor cells The present invention is directed to a treatment for cancer. Compositions and methods of treating cancer are included in the scope of the present invention. The compositions of the present invention include a composition prepared from tumor cells or tumor cell extra... | 09/08/2009 |
| 7563450 | UL16 binding protein 4 ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells. ... | 07/21/2009 |
| 7553494 | WT1 fusion proteins Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that sp... | 06/30/2009 |
| 7541044 | Administration of 5T4 antigen and immune response of cells expressing 5T4 and CEA antigens The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumor immune response in a human patient. ... | 06/02/2009 |
| 7473430 | Cancer cell targeting gene delivery method The inventive chimeric ligand in the form of a fusion polypeptide of a single-chain antibody specific for Tag-72 surface antigen and GaLV envelope glycoprotein shows high transduction efficiency to cancer cells, specifically infects target cells and efficiently deli... | 01/06/2009 |
| 7455846 | Immune potentiating compositions of cancer cells The present invention relates various compositions having an immunostimulatory molecule and animal cells cultured in the presence of at least one interferon (IFN) of type I or type II for time and conditions sufficient to enhance the antigen presenting function of t... | 11/25/2008 |
| 7438922 | Human prostate cell lines in cancer treatment Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumor specific antigens (“TSAs”) and/or tumor associated antigens (... | 10/21/2008 |
| 7432246 | Sir2 products and activities A novel compound, 2′/3′-O-acetyl-ADP-ribose, is provided. The compound is a mixture of the 2′ and 3′ regioisomers of O-acetyl-ADP ribose, and is formed nonenzymatically from 2′-O-acetyl-ADP-ribose, which is the newly discovered product of the reaction of S... | 10/07/2008 |
| 7427405 | Immunostimulatory oligonucleotide multimers The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary. ... | 09/23/2008 |
| 7419660 | Vaccines for treatment of lymphoma and leukemia The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immun... | 09/02/2008 |
| 7420037 | Heat shock protein-based vaccines and immunotherapies Hybrid antigens comprising an antigenic domain and improved heat shock protein binding domains are described which are useful for the induction of an immune response to the antigenic domain and thus can be used to treat infectious diseases and cancers that express a... | 09/02/2008 |
| 7410801 | Lambda phage display system and the process The present invention relates to a process of obtaining recombinant lambdoid bacteriophage with high density display of functional peptides and proteins on surface of said phage comprising of: constructing a donor plasmid having a nucleotide sequence that defines th... | 08/12/2008 |
| 7407944 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of... | 08/05/2008 |
| 7404963 | Flagellin-based adjuvants and vaccines The present invention provides adjuvants, vaccines and related methods that are useful in eliciting immune responses, particularly immune responses against tumor antigens. We discovered that flagellin is capable of inhibiting tolerance when it is administered in con... | 07/29/2008 |
| 7402317 | Anti-cancer vaccine There is disclosed a method of preparing a vaccine suitable for administration to humans for the prevention or treatment of cancer. The vaccine is prepared by culturing human cancer cells in a serum-free medium and recovering from the culture medium the cell surface... | 07/22/2008 |
| 7393921 | Prostate-specific polypeptide pamp and encoding nucleic acid molecules The present invention relates to novel prostate specific nucleic acid molecules and polypeptides and related methods for diagnosing or predicting susceptibility to a prostate neoplastic condition. ... | 07/01/2008 |
| 7387271 | Immunostimulatory combinations The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen. ... | 06/17/2008 |
| 7368119 | Compositions and methods for WT1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that sp... | 05/06/2008 |
| 7364741 | Peptides of human Papilloma virus for use in human T cell response inducing compositions A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of... | 04/29/2008 |
| 7361330 | Methods of using flt3-ligand in the treatment of fibrosarcoma Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma. ... | 04/22/2008 |
| 7361346 | Therapeutic compositions that produce an immune response The invention provides a method for stimulating the production of antibodies to a cryptic epitope on a soluble antigen by administering to a patient having such a cryptic epitope a binding agent that binds to the soluble antigen and forming a complex between the bin... | 04/22/2008 |
